Abuzzahab FS, Merwin GE, Zimmermann RL, Sherman MC (1977) A double-blind investigation of piracetam vs placebo in geriatric memory. Pharmacopsychiatry 10:49–56

Banfi S, Dorigotti L (1986) Experimental behavioural studies with oxiracetam on different types of chronic cerebral impairment. Clin Neuropharmacol 9:19–26

Brown R, Kulik J (1977) Flashbulb memories. Cognition 5:73–99

Chouinard G, Annable L, Ross-Chouinard A, Olivier M, Fontaine F (1983) Piracetam in elderly psychiatric patients with mild diffuse cerebral impairment. Psychopharmacol Bull 81:100–106

Claus JJ, Ludwig C, Mohr E, Giuffra M, Blin J, Chase TN (1991) Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam. Neurology 41:570–574

Cumin R, Bandle EF, Gamzu E, Haefely WE (1982) Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents. Psychopharmacology 78:104–111

Dunnett CW (1955) A multiple comparison procedure for comparing several treatments with a control. J Am Statist Assoc 50:1096–1121

Dunnett CW (1964) New tables for multiple comparisons with a control. Biometrics 20:482–491

Fitten LJ, Perryman KM, Gross PL, Fine H, Cummins J, Marshall C (1990) Treatment of Alzheimer's disease with short- and long-term oral THA and lecithin: a double-blind study. Am J Psychiatry 147:239–242

Gehan EA (1980) A generalized Wilcoxon test for comparing arbitrarily single censored samples. Biometrika 52:203–53

Häusler A, Monnet G, Borer C, Bhatnagar A (1989) Evidence that corticosterone is not an obligatory intermediate in aldosterone biosynthesis. J Steroid Biochem 34:567–570

Hjörther A, Browne E, Jakobsen K, Viskum P, Gyntelberg F (1986) Organic brain syndrome treated with oxiracetam. Acta Neurol Scand 75:271–276

Kalbfleisch JDS, Prentice RL (1980) The statistical analysis of failure time data. Wiley, New York

Mangoni A, Perin C, Smirne S, Piccolo I, DeFilippi F, Marchetti C, Motta A, Monza GC (1988) A double-blind placebo-controlled study with oxiracetam in demented patients administered the Luria-Nebraska neuropsychological battery. Drug Dev Res 14:217–222

Martignoni E, Petraglia F, Costa A, Bono G, Genazzini AR, Nappi G (1990) Dementia of the Alzheimer type and hypothalamus-pituitary-adrenocortical axis: changes in cerebrospinal fluid corticotropin releasing factor and plasma cortisol levels. Acta Neurol Scand 81:452–456

Mondadori C, Häusler A (1990) Aldosterone receptors are involved in the mediation of the memory-improving effects of piracetam. Brain Res 524:203–207

Mondadori C, Petschke F (1987) Do piractam-like compounds act centrally via peripheral mechanisms? Brain Res 435:310–314

Mondadori C, Ducret T, Petschke F (1989) Blockade of the nootropic action of piractam-like nootropics by adrenalectomy: an effect of dosage? Behav Brain Res 34:155–158

Mondadori C, Bhatnagar A, Borkowski J, Häusler A (1990) Involvement of a steroidal component in the mechanism of action of piractam-like nootropics. Brain Res 506:101–108

Müller J (1988) Regulation of aldosterone biosynthesis. Physiological and biochemical aspects, 2nd rev edn. Springer, Berlin Heidelberg New York, p 5

Murray CL, Fibiger HC (1986) The effect of pramiracetam (CI 879) on the acquisition of a radial arm maze task. Psychopharmacology 89:378–381

Schneider LS (1990) Tetrahydroaminoacridine and lecithin for Alzheimer's disease. N Engl J Med 323:919

Sourander LB, Portin R, Mölsä P, Lahdes A, Rinne UK (1987) Senile dementia of the Alzheimer type treated with aniracetam, a new nootropic agent. Psychopharmacology 91:90–95

Weiskrantz L, Mondadori C (1991) MK 801 can facilitate passive avoidance memory when retention is not present in control animals, and can fail to facilitate, when it is present. Psychopharmacology 105:145–150